The top industry player to seize this multibillion-dollar opportunity is Pfizer, which will sustain a 9.2% decline in annual sales forecast from 2023 to 2029 but will nevertheless hold the most dominant position in the infectious diseases space.
Tag Archive for: infection disease
Data recently unveiled showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
